Trimel Pharmaceuticals - Seeking positive EBITDA with Estrace
06 Agosto 2014 - 6:27AM
InvestorsHub NewsWire
Trimel
(TSX:TRL)
has acquired Canadian rights to Estrace (oral 17-beta estradiol)
for C$44.5m from Shire. This profitable asset, with US$9-10m in
annual sales, complements Trimel's existing hormone replacement
pipeline. The transaction fits with the goal to become EBITDA
positive within 12-18 months, although future Natesto-related
revenue (upon completion of a partnership transaction) will be the
key driver towards this objective.
Trimel
is a Canadian specialty pharmaceutical company. Natesto and Tefina
deliver testosterone through a bio-adhesive nasal gel drug delivery
technology platform, for male hypogonadism and female orgasmic
disorder (FOD), respectively. Estrace is being marketed for HRT in
Canada.
To view the full report, click on the following link: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals-
To view all of Edison's recently pubished research, click here.
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Trilogy International Pa... (TSX:TRL)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Trilogy International Partners Inc (Borsa di Toronto (TSX)): 0 articoli recenti
Più Trimel Pharmaceuticals Corp Articoli Notizie